Collaboration with hospitals, diagnostic labs, and medical institutes to generate datasets comparing digital pathology and traditional methods to present a solid case for the regulatory approval of their product.
Approval of AI-based tools needs to be a top priority for AI-based, digital pathology-focused companies as low-to-medium risk diagnostic avenues are an innovative way to transition from pharmaceutical to mainstream clinical applications in the digital pathology segment.
Digital Pathology: Roadmap to the Future of Medical Diagnosis is part of Frost & Sullivan's global Medical Devices & Imaging Growth Partnership Service program.

Frost & Sullivan's global TechVision practice is focused on innovation, disruption and convergence and provides a variety of technology-based newsletters and research services as well as growth consulting services. Its premier offering, the Top 50 Technologies program, identifies and evaluates the most valuable emerging and disruptive technologies enabling products with near-term potential. A unique feature of the TechVision program is an annual selection of 50 technologies that can generate convergence scenarios, possibly disrupt existing business models, and drive transformational growth. View a summary of our TechVision program by clicking on the following link: http://ifrost.frost.com/TechVision_Demo.

About Frost & Sullivan
For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Back to HCB News

Pathology Homepage